Page 45 - Fact Sheets News Today

MRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron VariantAuthorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent VaccinesCAMBRIDGE, MA / ACCESSWIRE / December 8, 2022 / Moderna

Bebtelovimab is expected to have reduced activity against certain emerging Omicron subvariants of SARS-CoV-2.

Clovis Oncology, Inc. today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation... | October 27, 2022

On 19 and 20 October 2022, Slovenian Nuclear Safety Administration hosted the 24th meeting of the Working Group on Emergencies (WGE) established by the Heads of European Radiological Protection Competent Authorities (HERCA).

Data indicate durable immune response from bivalent booster after three months of follow-upmRNA-1273.214 also demonstrated potent response to Omicron BA.2.75CAMBRIDGE, MA / ACCESSWIRE / October 19, 2022

The papaya benefits include reduced risk of high blood pressure, increased gut health & anticancer properties. Read on to find more in 2023.

WASHINGTON, D.C. -- The nations only pre-exposure treatment for COVID-19 is getting an advisory today about its limited effectiveness.

On August 19, 2022, the United States Department of Health and Human Services, Department of Labor, and Department of the Treasury (the Departments) published a new final rule (Final Rule)...

On August 19, 2022, the United States Department of Health and Human Services, Department of Labor, and Department of the Treasury (the Departments) published a new final rule (Final...

Investegate announcements from BioNTech SE, Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age